Advertisement
Advances in Pediatrics

Immunization Update

  • Ayesha Mirza
    Affiliations
    Pediatric Infectious Diseases and Immunology, University of Florida, 653-1 West 8th Street, L-13, Jacksonville, FL 32209, USA
    Search for articles by this author
  • Mobeen H. Rathore
    Correspondence
    Corresponding author. University of Florida, 653-1 West 8th Street, L-13, Department of Pediatrics, 3rd Floor/LRC, Jacksonville, FL 32209.
    Affiliations
    Pediatric Infectious Diseases and Immunology, University of Florida, 653-1 West 8th Street, L-13, Jacksonville, FL 32209, USA

    Wolfson Children's Hospital, 800 Prudential Drive, Jacksonville, FL 32207, USA
    Search for articles by this author
      Immunization remains the most cost-effective method of delivering health care, particularly for children. The National Commission on Prevention Priorities recent update to the 2001 ranking of clinical preventive services listed childhood immunization series as second only to aspirin chemoprophylaxis for the prevention of cardiovascular events in adults [
      • Maciosek M.V.
      • Coffiel A.B.
      • Edwards N.M.
      • et al.
      Priorities among effective clinical preventive services.
      ]. Both 2005 and 2006 saw several changes in the childhood and adolescent immunization schedules with the approval of several long-awaited vaccines. The purpose of this article is to provide readers with a comprehensive overview of the new changes and developments in the already hectic childhood and now adolescent immunization schedules (Fig. 1, Fig. 2). For the sake of this discussion, the authors have divided this article into new vaccines for adolescents followed by new vaccines for children as well as any updates in the vaccination schedules for children.
      Figure thumbnail gr1
      Fig. 1Recommended immunization schedule for persons aged 0 to 6 years—United States, 2007.
      Figure thumbnail gr2
      Fig. 2Recommended immunization schedule for persons aged 7 to 18 years—United States, 2007.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Advances in Pediatrics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Maciosek M.V.
        • Coffiel A.B.
        • Edwards N.M.
        • et al.
        Priorities among effective clinical preventive services.
        Am J Prev Med. 2006; 33: 52-61
        • CDC
        Achievements in public health: hepatitis B vaccination-United States, 1982–2002.
        MMWR Morb Mortal Wkly Rep. 2002; 51: 549-552
        • Cherry J.D.
        The epidemiology of pertussis: a comparison of the epidemiology of the disease pertussis with the epidemiology of Bordetella pertussis infection.
        Pediatrics. 2005; 115: 1422-1427
        • CDC
        Preventing tetanus, diphtheria and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines. Recommendations of the Advisory Committee on Immunization Practices (ACIP).
        MMWR Recomm Rep. 2006; 55: 1-34
        • CDC
        Preventing tetanus, diphtheria and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel.
        MMWR Recomm Rep. 2006; 55: 1-37
        • Hewlett E.L.
        • Edwards K.M.
        Pertussis- not just for kids.
        N Engl J Med. 2005; 352: 1215-1222
        • CDC
        Pertussis-United States, 1997–2000.
        MMWR Morb Mortal Wkly Rep. 2002; 51: 73-76
        • Cherry J.D.
        The science and fiction of the resurgence of ‘pertussis’.
        Pediatrics. 2003; 112: 405-406
        • Jenkinson D.
        Duration of effectiveness of pertussis vaccine: evidence from a 10 year community study.
        BMJ. 1988; 296: 612-614
        • Salmaso S.
        • Mastrantonio P.
        • Tozzi A.E.
        • et al.
        Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience.
        Pediatrics. 2001; 108: e81
        • Tan T.
        • Trindade E.
        • Skowronski D.
        Epidemiology of pertussis.
        Pediatr Infect Dis J. 2005; 24: S10-S18
        • Cherry J.D.
        Epidemiology of pertussis.
        Pediatr Infect Dis J. 2006; 25: 361-362
        • Bass J.W.
        • Zacher L.L.
        Do newborn infants have passive immunity to pertussis?.
        Pediatr Infect Dis J. 1989; 8: 352-353
        • Cherry J.D.
        Epidemiological, clinical and laboratory aspect of pertussis in adults.
        Clin Infect Dis. 1999; 28: S112-S117
        • Schmitt-Grohé S.
        • Cherry J.D.
        • Heininger U.
        • et al.
        Pertussis in German adults.
        Clin Infect Dis. 1995; 21: 860-866
        • Mink C.M.
        • Cherry J.D.
        • Christenson P.
        • et al.
        A search for Bordetella pertussis infection in university students.
        Clin Infect Dis. 1992; 12: 464-471
        • Bisgard K.M.
        • Pascual B.F.
        • Ehresmann K.R.
        • et al.
        Infant Pertussis-who was the source?.
        Pediatr Infect Dis J. 2004; 23: 985-989
        • Cattaneo L.A.
        • Reed G.W.
        • Haase D.H.
        • et al.
        The seroepidmiology of Bordetella pertussis infections: a study of persons ages 1–65 years.
        J Infect Dis. 1996; 173: 1256-1259
        • Birkebaek N.H.
        • Kristiansen M.
        • Seefeldt T.
        • et al.
        Bordetella pertussis and chronic cough in adults.
        Clin Infect Dis. 1999; 29: 1239-1242
        • Wright S.W.
        • Edwards K.M.
        • Decker M.D.
        • et al.
        Pertussis infection in adults with persistent cough.
        JAMA. 1995; 273: 1044-1046
        • Senzilet L.D.
        • Halperin S.A.
        • Spika J.S.
        • et al.
        Pertussis is a frequent cause of prolonged cough illness in adults and adolescents.
        Clin Infect Dis. 2001; 32: 1691-1697
        • Strebel P.
        • Nordin J.
        • Edwards K.
        • et al.
        Population based incidence of pertussis among adolescents and adults, Minnesota, 1995-1996.
        J Infect Dis. 2001; 183: 1353-1359
        • Ward J.I.
        • Cherry J.D.
        • Chang S.J.
        • et al.
        Efficacy of an acellular pertussis vaccine among adolescents and adults.
        N Engl J Med. 2005; 353: 1555-1563
      1. US Food and Drug Administration. Approval for Boostrix. Available at: www.fda.gov/cber/products/tdapgla050305.htm. Accessed January 19, 2007.

      2. US Food and Drug Administration. Approval for Adacel. Available at: http://www.fda.gov/cber/products/tdapave012306.htm. Accessed January 19, 2007.

        • Food and Drug Administration
        Vaccines and related biological products advisory committee, 2005: FDA Boostrix® briefing information.
        US Department of Health and Human Services, Food and Drug Administration, Rockville (MD)2005 (Available at:) (. Accessed February 2, 2007)
        • Food and Drug Administration
        Vaccines and related biological products advisory committee, 2005: FDA Boostrix® briefing information: FDA Adacel® briefing information.
        US Department of Health and Human Services, Food and Drug Administration, Rockville (MD)2005 (Available at:) (. Accessed February 2, 2007)
        • Cherry J.
        • Gornbein J.
        • Heininger U.
        • et al.
        A search for serologic correlates of immunity to Bordetella pertussis cough illnesses.
        Vaccine. 1998; 16: 1901-1906
        • Food and Drug Administration
        Vaccines and Related Biologicals products advisory Committee.
        Food and Drug Administration, Bethesda (MD)1997 (Available at:) (Accessed February 2, 2007)
        • Pichichero M.E.
        • Casey J.R.
        Acellular pertussis vaccines for adolescents.
        Pediatr Infect Dis J. 2005; 24: S117-S126
        • Pichichero M.E.
        • Rennels M.B.
        • Edwards K.M.
        • et al.
        Combined tetanus, diphtheria and 5 component pertussis vaccine for use in adults and adolescents.
        JAMA. 2005; 293: 3003-3011
        • Schmitt H.J.
        • von Konig C.H.
        • Neiss A.
        • et al.
        Efficacy of acellular pertussis vaccine in early childhood after household exposure.
        JAMA. 1996; 275: 37-41
        • Gustafsson L.
        • Hallander H.O.
        • Olin P.
        • et al.
        A controlled trial of a two component acellular, a five component acellular and a whole cell pertussis vaccine.
        N Engl J Med. 1996; 334 ([published correction in N Engl J Med 334: 1207, 1996]): 349-355
        • CDC
        Immunization of adolescents: recommendations of the Advisory Committee on Immunization Practices, the American Academy of Pediatrics, the American Academy of Family Physicians and the American Medical Association.
        MMWR Recomm Rep. 1996; 45: 1-16
        • American Academy of Pediatrics
        Tetanus(lockjaw).
        in: Pickering L.K. Baker C.J. Long S.S. Red Book: 2006 Report of the Committee on Infectious Dseases. 27th edition. American Academy of Pediatrics, Elk Grove Village (IL)2006: 648-653
        • Halperin S.
        • Sweet L.
        • Baxendale D.
        How soon after prior tetanus-diphtheria vaccination can one give the adult formulation tetanus-diphtheria pertussis vaccine?.
        Pediatr Infect Dis J. 2006; 25: 195-200
        • Public Health Agency of Canada
        An Advisory Committee Statement (ACS), National Advisory on Immunization (NACI): interval between administration of vaccines against diphtheria, tetanus and pertussis.
        Can Commun Dis Rep. 2005; 31: 17-24
      3. Committee on Infectious Diseases. Prevention of pertussis among adolescents: recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine.
        Pediatrics. 2006; 117: 965-978
        • Wendelboe A.M.
        • Van Rie A.
        • Salmaso S.
        • et al.
        Duration of immunity against pertussis after infection or vaccination.
        Pediatr Infect Dis J. 2005; 24: S58-S61
        • American Academy of Pediatrics
        Pertussis.
        in: Pickering L.K. Baker C.J. Long S.S. Red Book: 2006 Report of the Committee on Infectious Diseases. 27th edition. American Academy of Pediatrics, Elk Grove Village (IL)2006: 498-520
        • Healy C.M.
        • Munoz F.M.
        • Rench M.A.
        • et al.
        Prevalence of pertussis antibodies in maternal delivery, cord and infant serum.
        J Infect Dis. 2004; 190: 335-340
      4. Committee on Infectious Diseases. Prevention and control of meningococcal disease: recommendations for use of meningococcal vaccines in pediatric patients.
        Pediatrics. 2005; 116: 496-505
        • CDC
        Prevention and control of meningococcal disease: recommendations of the advisory committee on immunization practices (ACIP).
        MMWR Recomm Rep. 2000; 49: 1-10
        • Harrison L.H.
        • Pass M.A.
        • Mendelsohn A.B.
        • et al.
        Invasive meningococcal disease in adolescents and young adults.
        JAMA. 2001; 286: 694-699
        • CDC
        Prevention and control of meningococcal disease: recommendations of the advisory committee on immunization practices (ACIP).
        MMWR Recomm Rep. 2005; 54: 1-21
        • WHO Position Paper
        Meningococcal vaccines: polysaccharide and polysaccharide conjugate vaccines.
        Weekly Epidemiologic Record. 2002; 77: 329-340
        • Rosenstein N.E.
        • Perkins B.A.
        • Stephens D.S.
        • et al.
        The changing epidemiology of meningococcal disease in the United States, 1992–1996.
        J Infect Dis. 1999; 180: 1894-1901
        • Hankins W.A.
        • Gwaltney Jr., J.M.
        • Hendley J.O.
        • et al.
        Clinical and serological evaluation of a meningococcal polysaccharide vaccine: groups A, C, Y, and W135.
        Proc Soc Exp Biol Med. 1982; 169: 54-57
        • Artenstein M.S.
        • Gold R.
        • Zimmerly J.G.
        • et al.
        Prevention of meningococcal disease by group C polysaccharide vaccine.
        N Engl J Med. 1970; 282: 417-420
        • American Academy of Pediatrics
        Meningococcal infections.
        in: Pickering L.K. Baker C.J. Long S.S. McMillan J.A. Red Book: 2006 Report of the Committee on Infectious Diseases. 27th edition. American Academy of Pediatrics, Elk Grove Village (IL)2006: 452-460
        • CDC
        Meningococcal disease and college students. recommendations of the Advisory Committee in Immunization Practices (ACIP).
        MMWR Recomm Rep. 2000; 49: 11-20
        • Froeschle J.
        Meningococcal disease in college students.
        Clin Infect Dis. 1999; 29: 215-216
        • Harrison L.H.
        • Dwyer D.M.
        • Maples C.T.
        • et al.
        Risk of meningococcal infection in college students.
        JAMA. 1999; 281: 1906-1910
        • Neal K.R.
        • Nguyen-Van-Tam J.
        • Monk P.
        • et al.
        Invasive meningococcal disease among university undergraduates: association with universities providing relatively large amounts of catered hall accommodations.
        Epidemiol Infect. 1999; 122: 351-357
        • Gardner P.
        Prevention of meningococcal disease.
        N Engl J Med. 2006; 355: 1466-1473
      5. US Department of Health and Human Services, Food and Drug Administration, Centers for Biologics Evaluation and Research. Product approval information-licensing action. 2005. Available at: www.fda.gov/cber/products/mpdtave011405.htm. Accessed January 19, 2007.

        • Maiden M.C.
        • Stuart J.M.
        Carriage of serogroup C meningococci one year after meningococcal C conjugate polysaccharide vaccination.
        Lancet. 2002; 359: 1829-1831
        • Ramsay M.
        • Andrews N.J.
        • Trotter C.L.
        • et al.
        Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis.
        BMJ. 2003; 326: 365-366
        • Shepard C.W.
        • Ortega-Sanchez I.R.
        • Scott II, R.D.
        • et al.
        Cost effectiveness of conjugate meningococcal vaccination strategies in the United States.
        Pediatrics. 2005; 115: 1220-1232
        • CDC
        Update: Guillain-Barré Syndrome among recipients of Menactra® meningococcal conjugate vaccine-United States, June 2005-September 2006.
        MMWR Recomm Rep. 2006; 55: 1120-1123
        • Trotter Caroline L.
        • Mary E.
        • et al.
        Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines.
        FEMS Microbiol Rev. 2007; 31: 101-107
        • Cates Jr., W.
        • the American Social Health Association Panel
        Estimates of the incidence and prevalence of sexually transmitted diseases in the United States.
        Sex Transm Dis. 1999; 26: S2-S7
        • Weinstock H.
        • Berman S.
        • Cates Jr., W.
        Sexually transmitted diseases among American youth: incidence and prevalence estimates, 2000.
        Perspect Sex Reprod Health. 2004; 36: 6-10
        • CDC
        Genital HPV infection fact sheet.
        CDC National Prevention Information Network, Rockville (MD)2004
      6. World Health Organization. Report of the Consultation on Human Papilloma Vaccines. Geneva, April 2005. Available at: http://www.who.int/vaccine_research/documents/816%20%20HPV%20meeting.pdf. Accessed January 20, 2007.

        • Franco E.L.
        • Villa L.L.
        • Richardson H.
        • et al.
        Epidemiology of cervical human papilloma virus infection.
        in: Franco J. Monsonego E.l. New developments in cervical cancer screening and prevention. Blackwell Science, Oxford(UK)1997: 14-22
        • Tortolero-Luna G.
        Epidemiology of genital human papillomavirus.
        Hematol Oncol Clin North Am. 1999; 13: 245-257
        • American Cancer Society
        Cancer facts and figures 2005.
        Atlanta (GA), American cancer Society2005 (p. 1–60)
        • Jemal A.
        • Murray T.
        • Ward E.
        • et al.
        Cancer statistics 2005.
        CA Cancer J Clin. 2005; 55: 10-30
        • Ferlay J.
        • Bray F.
        • Pisani P.
        • et al.
        GLOBOCAN 2002: Cancer incidence, mortality and prevalence worldwide, version 2.0.
        ([IARC CancerBase No.5]) IARC Press, Lyon (France)2004
        • Bosch F.X.
        • Lorincz A.
        • Muňoz N.
        • et al.
        The causal relation between human papillomavirus and cervical cancer.
        J Clin Pathol. 2002; 55: 244-265
        • Walboomers J.M.
        • Jacobs M.V.
        • Manos M.M.
        • et al.
        Human papillomavirus is a necessary cause of invasive cervical cancer worldwide.
        Journal of Pathology. 1999; 189: 12-19
        • González Intxaurraga M.A.
        • Stankovic R.
        • Sorli R.
        • et al.
        HPV and carcinogenesis.
        Acta Dermatovenerol. 2002; 11: 1-8
        • Sirovich B.e.
        • Welch H.g.
        The frequency of pap smear screening in the United States.
        J Gen Intern Med. 2004; 19: 243-250
        • Nanda K.
        • McCrory D.C.
        • Myers E.R.
        • et al.
        Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review.
        Ann Intern Med. 2000; 132: 810-819
        • Gravitt P.E.
        • Jamshidi R.
        Diagnosis and management of oncogenic cervical human papillomavirus infection.
        Infect Dis Clin North Am. 2005; 19: 439-458
        • Wiley D.J.
        • Douglas J.
        • Beutner K.
        • et al.
        External genital warts: diagnosis, treatment and prevention.
        Clin Infect Dis. 2002; 35: S210-S224
        • Abramson A.L.
        • Nouri M.
        • Mullooly V.
        • et al.
        Latent human papillomavirus infection is comparable in the larynx and trachea.
        J Med Virol. 2004; 72: 473-477
        • Palefsky J.
        • Holly E.
        Immunosuppression and co-infection with HIV.
        J Natl Cancer Inst Monogr. 2003; 31: 41-46
        • Ho G.F.
        • Bierman R.
        • Beardsley L.
        • et al.
        Natural history of cervicovaginal papillomavirus infection in young women.
        N Engl J Med. 1998; 338: 423-428
        • Franco E.L.
        • Villa L.L.
        • Sobrinho J.P.
        • et al.
        Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high risk area for cervical cancer.
        J Infect Dis. 1999; 180: 1415-1423
        • Kjaer S.K.
        • van den Brule A.J.
        • Paull G.
        • et al.
        Type specific persistence of high risk human papillomavirus(HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study.
        BMJ. 2002; 325: 572
        • Schlecht N.F.
        • Kulaga S.
        • Robitaille J.
        • et al.
        Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia.
        JAMA. 2001; 286: 3106-3114
        • Munoz N.
        • Bosch F.
        • de Sanjose S.
        • et al.
        Epidemiologic classification of human papillomavirus types associated with cervical cancer.
        N Engl J Med. 2003; 348: 518-527
        • Castellsague X.
        • Munoz N.
        Cofactors in human papillomavirus carcinogenesis-role of parity, oral contraceptives and tobacco smoking.
        J Natl Cancer Inst Monogr. 2003; : 20-28
        • Moreno V.
        • Bosch F.X.
        • Munoz
        • et al.
        Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study.
        Lancet. 2002; 359: 1085-1092
        • Green J.
        • Berrington de Gonzalez A.
        • Smith J.S.
        • et al.
        Human papillomavirus infection and use of oral contraceptives.
        Br J Cancer. 2003; 88: 1713-1720
        • Smith J.S.
        • Herrero R.
        • Bosetti C.
        • et al.
        Herpes simplex virus-2 as a human papillomavirus cofactor in the etiology of invasive cervical cancer.
        J Natl Cancer Inst. 2002; 94: 1604-1613
        • Wallin K.L.
        • Wilkund F.
        • Luostarinen T.
        • et al.
        A population- based prospective study of Chlamydia trachomatis infection and cervical carcinoma.
        Int J Cancer. 2002; 101: 371-374
        • Castle P.E.
        • Hillier S.L.
        • Rabe L.K.
        • et al.
        An association of cervical inflammation with high grade cervical neoplasia in women infected with oncogenic human papillomavirus (HPV).
        Cancer Epidemiol Biomarkers Prev. 2001; 10: 1021-1027
      7. US Food and Drug Administration. Approval Gardasil. Available at: www.fda.gov/cber/products/hpvmer060806.htm. Accessed January 19, 2007.

        • Harper D.M.
        • Franco E.L.
        • Wheeler C.
        • et al.
        GlaxoSmithKline HPV Vaccine Study Group. Efficacy of a bivalent L1 virus like particle vaccine in prevention of infection with human papilloma virus types 16 and 18 in young women: a randomised controlled trial.
        Lancet. 2004; 364: 1757-1765
        • Villa L.L.
        • Costa R.L.
        • Petta C.A.
        • et al.
        Prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicenter phase II efficacy trial.
        Lancet Oncol. 2005; 6: 271-278
      8. Skjeldestad FE. Prophylactic quadrivalent human papillomavirus (HPV) types 6, 11, 16 and 18) L1 virus-like particle (VLP) vaccine (Gardasil) reduces cervical intraepithelial neoplasia (CIN) 2/3 risk [abstract LB-8a]. In: Proceedings of the 43rd Annual Meeting of the Infectious Diseases Society of America. Alexandria (VA): Infectious Diseases Society of America; 2005. p. 53.

        • Block S.L.
        • Nolan T.
        • Sattler C.
        • et al.
        Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6,11,16 and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women.
        Pediatrics. 2006; 118: 2135-2145
        • Friedman L.S.
        • Kahn J.
        • Middleman A.B.
        • et al.
        Human papillomavirus (HPV) vaccine: a position statement of the Society for Adolescent Medicine.
        J Adolesc Health. 2006; 39: 620
      9. GlaxoSmithKline Biologicals. Study to compare immunogenicity of GSK's cervical cancer candidate vaccine, Cervarix®, to Merck's Gardasil®. Available at: http://www.gsk.com/ControllerServlet?appId=4&pageId=402&newsid=959. Accessed January 27, 2007.

        • Colgrove J.
        The ethics and politics of compulsory HPV vaccination.
        N Engl J Med. 2006; 23: 2389-2391
        • Dempsey A.F.
        • Zimet G.D.
        • Davis R.L.
        • et al.
        Factors associated with parental acceptance of human papillomavirus vaccines: a randomized intervention study of written information about HPV.
        Pediatrics. 2006; 117: 1486-1493
        • Brabin L.
        • Roberts S.A.
        • Farzaneh F.
        • et al.
        Future acceptance of adolescent human papillomavirus vaccination: a survey of parental attitudes.
        Vaccine. 2006; 24: 3087-3094
        • Palefsky J.M.
        • Minkoff H.
        • Kalish L.A.
        • et al.
        Cervicovaginal human papillomavirus infection in human immunodeficiency virus-1 (HIV)-positive and high risk HIV-negative women.
        J Natl Cancer Inst. 1999; 91: 226-236
      10. IMPAACT-International maternal-pediatric-adolescent AIDS clinical trials unit. Available at: http://pactg.s-3.com/members/ps/1047/ps1047.htm. Accessed January 26, 2007.

      11. CDC. National Immunization Program: rotavirus diarrhea Q & A. 2006. Available at: http://www.cdc.gov/nip/diseases/rota/rotavirus.htm. Accessed January 20, 2007.

        • Velaquez F.R.
        • Matson D.O.
        • Calva J.J.
        • et al.
        Rotavirus infections in infants as protection against subsequent infections.
        N Engl J Med. 1996; 335: 1022-1028
        • Rodriguez W.J.
        • Kim H.W.
        • Brandt C.D.
        • et al.
        Longitudinal study of rotavirus infection and gastroenteritis in families served by a pediatric medical practice: clinical and epidemiologic observations.
        Pediatr Infect Dis J. 1987; 6: 170-176
        • Glass K.I.
        • Kilgore P.E.
        • Holman R.C.
        • et al.
        The epidemiology of rotavirus diarrhea in the United States: surveillance and estimates of disease burden.
        J Infect Dis. 1996; 174: S5-S11
        • Fisher T.K.
        • Bresee J.S.
        • Glass R.I.
        Rotavirus vaccines and the prevention of hospital-acquired diarrhea in children.
        Vaccine. 2004; 22: S49-S54
        • Ford Jones E.L.
        • Wang E.
        • Petric M.
        • et al.
        Rotavirus-associated diarrhea in outpatient settings and childcare centers. The Greater Toronto Area/Peel Region PRESI Study Group. Pediatric Rotavirus Epidemiology Study for Immunization.
        Arch Pediatr Adolesc Med. 2000; 154: 586-593
        • Reves R.R.
        • Morrow M.
        • Bartlett III, A.V.
        • et al.
        Child day care increases the risk of clinic visits for acute diarrhea and diarrhea due to rotavirus.
        Am J Epidemiol. 1993; 1137: 97-107
        • Gonzalez-Carretero P.
        • Noguera A.
        • Fortuny C.
        Rotavirus gastroenteritis leading to secondary bacteremia in previously healthy infants.
        Pediatrics. 2006; 118: 2255-2256
        • Mel E.
        • Nahum E.
        • Lowenthal A.
        • et al.
        Extended spectrum beta-lactamase positive Escherichia coli bacteremia complicating rotavirus gastroenteritis.
        Pediatr Infect Dis J. 2006; 25: 962
        • Lowenthal A.
        • Livni G.
        • Amir J.
        • et al.
        Secondary bacteremia after rotavirus gastroenteritis in infancy.
        Pediatrics. 2006; 117: 224-226
        • Avendano P.
        • Matson D.O.
        • Long J.
        • et al.
        Costs associated with office visits for diarrhea in infants and toddlers.
        Pediatr Infect Dis J. 1993; 12: 897-902
        • Tucker A.W.
        • Haddix A.C.
        • Bresee J.S.
        • et al.
        Cost-effectiveness analysis of a rotavirus immunization program for the United States.
        JAMA. 1998; 279: 1371-1376
      12. Parashar U., Issues of human-bovine vaccine. Paper presented at the Meeting of the Advisory Committee on Immunization practices, Centers for Disease Control and Prevention. Atlanta, GA, June30, 2005.

        • Parashar U.D.
        • Holman R.C.
        • Clarke M.J.
        • et al.
        Hospitalizations associated with rotavirus diarrhea in the United States, 1993 through 1995; surveillance based on the new ICD-9-CM rotavirus-specific diagnostic code.
        J Infect Dis. 1997; 177: 13-17
        • Parashar U.D.
        • Gibson C.J.
        • Bresee J.S.
        • et al.
        Rotavirus and severe childhood diarrhea.
        Emerg Infect Dis. 2006; 12: 304-306
        • Parashar U.D.
        • Hummelman E.G.
        • Bresee J.S.
        • et al.
        Global illness and deaths caused by rotavirus disease in children.
        Emerg Infect Dis. 2003; 9: 565-572
        • Wilhelmi I.
        • Roman E.
        • Sanchez-Fauqier A.
        Viruses causing gastroenteritis.
        Clin Microbiol Infect. 2003; 9: 247-262
        • Santos N.
        • Hoshimo Y.
        Global distribution of rotavirus serotypes/genotypes and its implication for the development and implementation of an effective rotavirus vaccine.
        Rev Med Virol. 2005; 15: 29-56
        • Offit P.A.
        • Clark H.F.
        Rotavirus.
        in: Mandel G.L. Bennett J.E. Dolin R. Mandell, Douglas, and Bennett's principles and practice of infectious siseases. 5th edition. Churchill Livingstone, New York2000: 1696-1703
        • Offit P.A.
        Immunologic determinants of protection against rotavirus disease.
        Curr Top Microbiol Immunol. 1994; 185: 229-254
        • .Moulton L.H.
        • Staat M.A.
        • Santosham M.
        • et al.
        The protective effectiveness of natural rotavirus infection in an American Indian population.
        J Infect Dis. 1998; 178: 1562-1566
        • O'Ryan M.L.
        • Matson D.O.
        • Estes M.K.
        • et al.
        Anti-rotavirus G type-specific and isotype-specific antibodies in children with natural rotavirus infections.
        J Infect Dis. 1994; 169: 504-511
        • Velazquez F.R.
        • Matson D.O.
        • Guerrant M.L.
        • et al.
        Serum antibody as a marker of protection against natural rotavirus infection and disease.
        J Infect Dis. 2000; 182: 1602-1609
        • Kapikian A.Z.
        • Hoshino Y.
        • Chanock R.M.
        Rotaviruses.
        in: Knipe D.M. Howley P.m. griffin D.E. Fields virology. 4th edition. Lippincott Williams & Wilkins, Philadelphia2001: 1787-1825
        • Matson D.O.
        • Estes M.K.
        • Burns J.W.
        • et al.
        Serotype variation of human group A rotaviruses in two regions of the USA.
        J Infect Dis. 1990; 162: 605-614
        • Griffin D.D.
        • Kirkwood C.D.
        • Parashar U.D.
        • et al.
        Surveillance of rotavirus strains in the United States: identification of unusual strains. The National Rotavirus Strain Surveillance System Collaborating Laboratories.
        J Clin Microbiol. 2000; 38: 2784-2787
        • Bresee J.S.
        • Glass R.I.
        • Ivanoff B.
        • et al.
        Current status and future priorities for rotavirus vaccine development, evaluation and implementation in developing countries.
        Vaccine. 1999; 17: 2207-2222
      13. Advisory Committee on Immunization Practices. Rotavirus vaccine for the prevention of rotavirus gastroenteritis among children: recommendations of the Advisory Committee on Immunization Practices.
        MMWR Recomm Rep. 1999; 48: 1-20
        • CDC
        Suspension of rotavirus vaccine after reports of intussusception-United States, 1999.
        Morb Mortal Wkly Rep. 2004; 53: 786-789
      14. Global Alliance for Vaccine Immunization (GAVI). GAVI and The Vaccine Fund announce $60 million boost to accelerate development of life saving vaccines. Press release. February 11, 2003. Available at: http://www.gavialliance.org/Media_Center/Press_Release/archive_2003.php. Accessed January 22, 2007.

      15. US Food and Drug Administration. Approval Rotateq®. Available at:. http://www.fda.gov/cber/products/rotamer020306.htm. Accessed January 23, 2007.

      16. Rotateq (rotavirus vaccine, live, oral, pentavalent) prescribing information for the United States.
        Merck and Co., Inc.,, Whitehouse Station (NJ)2006
        • Vesikari T.
        • Matson D.O.
        • Dennehy P.
        • et al.
        Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine.
        N Engl J Med. 2006; 354: 23-33
      17. CDC. Prevention of rotavirus gastroenteritis among infants and children. Recommendations of the advisory Committee on Immunization Practices (ACIP). Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5512a1.htm. Accessed January 23, 2007.

        • American Academy of Pediatrics Committee on Infectious Diseases
        Policy statement. Prevention of rotavirus Ddisease: guidelines for use of Rotavirus vaccine.
        Pediatrics. 2007; 119: 171-182
        • Ruiz-Palacios G.M.
        • Perez-Schael I.
        • Velázquez F.R.
        • et al.
        Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis.
        N Engl J Med. 2006; 354: 11-22
        • Iwamoto M.
        • Saari T.N.
        • McMahon S.R.
        • et al.
        A survey of pediatricians on the reintroduction of a rotavirus vaccine.
        Pediatrics. 2003; 112: e6-e10
        • Kempe A.
        • Daley M.F.
        • Parashar U.D.
        • et al.
        Will pediatricians adopt the new rotavirus vaccine?.
        Pediatrics. 2007; 119: 1-10
      18. CDC. CDC vaccine price list. Available at: www.cdc.gov/nip/vfc/cdc_vac_price_list.htm. Accessed January 24, 2007.

      19. GAVI Alliance. Available at: http://www.gavialliance.org/Media_Center/Press_Releases/berlin2006/pr_berlin_newvaccines_29nov2006_en.php. Accessed January 24, 2007.

        • Seward J.F.
        • Watson B.M.
        • Peterson C.L.
        • et al.
        Varicella disease after introduction of varicella vaccine in the United States, 1995–2000.
        JAMA. 2002; 287: 606-611
        • Davis M.M.
        • Patel M.S.
        • Gebremariam A.
        Decline in mortality due to varicella-related hospitalizations and expenditures for children and adults after introduction of varicella vaccine in the United States.
        Pediatrics. 2004; 114: 786-792
        • Nguyen H.Q.
        • Jumaan A.O.
        • Seward J.F.
        Decline in mortality due to varicella after implementation of varicella vaccination in the United States.
        N Engl J Med. 2005; 352: 450-458
        • Galil K.
        • Lee B.
        • Strine T.
        • et al.
        Outbreak of varicella at a day-care center despite vaccination.
        N Engl J Med. 2002; 347: 1909-1915
        • Tugwell B.D.
        • Lee L.E.
        • Gillette H.
        • et al.
        Chicken pox outbreak in a highly vaccinated school population.
        Pediatrics. 2004; 113: 455-459
        • Lee B.R.
        • Feaver S.L.
        • Miller C.A.
        • et al.
        An elementary school outbreak of varicella attributed to vaccine failure: policy implications.
        J Infect Dis. 2004; 190: 477-483
        • Lopez A.S.
        • Guris D.
        • Zimmerman L.
        • et al.
        One dose of varicella vaccine does not prevent school outbreaks: is it time for a second dose?.
        Pediatrics. 2006; 117: e1070-e1077
        • Vazquez M.
        • LaRussa P.S.
        • Gershon A.A.
        • et al.
        Effectiveness over time of varicella vaccine.
        JAMA. 2004; 291: 851-855
        • Kuter B.
        • Matthews H.
        • Shinefield H.
        • et al.
        Ten year follow-up of healthy children who received one or two injections of varicella vaccine.
        Pediatr Infect Dis J. 2004; 23: 132-137
        • White C.J.
        • Kuter B.J.
        • Ngai A.
        • et al.
        Modified cases of chickenpox after varicella vaccination: correlation of protection with antibody response.
        Pediatr Infect Dis J. 1992; 11: 19-23
        • Arvin A.
        • Gershon A.
        Control of varicella. Why is a two-dose schedule necessary?.
        Pediatr Infect Dis J. 2006; 25: 475-476
      20. CDC. ACIP provisional recommendations. Available at: http://www.cdc.gov/nip/vaccine/varicella/varicella_acip_recs_prov_june_2006.pdf. Accessed January 25, 2007.

        • Liebermann J.M.
        • Williams W.R.
        • Miller J.M.
        • et al.
        The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody.
        Pediatr Infect Dis J. 2006; 25: 615-622
        • Knuf M.
        • Habermehl P.
        • Zepp F.
        • et al.
        Immunogenicity and safety of two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children.
        Pediatr Infect Dis J. 2006; 25: 12-18
      21. CDC. National, state, and urban area vaccination coverage among children aged 19-35 months, United States, 2005. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5536a2.htm. Accessed January 30, 2007.

        • Reef S.E.
        • Cochi S.L.
        The evidence for the elimination of rubella and congenital rubella syndrome in the United States: a public health achievement.
        Clin Infect Dis. 2006; 43: S123-S125
        • Best J.M.
        • Castillo-Solorzano C.
        • Spika J.S.
        Reducing the global burden of congenital rubella syndrome: Report of the World Health Organization Steering Committee on research related to measles and rubella vaccines and vaccination, June 2004.
        J Infect Dis. 2005; 192: 1890-1897
        • Vesikari T.
        • Baer M.
        • Willems P.
        Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.
        Pediatr Infect Dis J. 2007; 26: 153-158
        • Shinefield H.
        • Black S.
        • Thear M.
        • et al.
        Safety and immunogenicity of a measles, mumps, rubella and varicella vaccine given with combined Haemophilus influenzae type b conjugate/hepatitis B vaccines and combined diphtheria-tetanus-acellular pertussis vaccines.
        Pediatr Infect Dis J. 2006; 25: 287-292
        • CDC
        Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP).
        MMWR Recomm Rep. 2006; 55: 1-23
        • Armstrong G.L.
        • Bell B.P.
        Hepatitis A virus infection in the United States: model-based estimates and implications for childhood immunization.
        Pediatrics. 2002; 109: 839-845
        • CDC
        Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP).
        MMWR Recomm Rep. 1996; 48: 1-30
        • CDC
        Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP).
        MMWR Recomm Rep. 1999; 48: 1-37
        • Wasley A.
        • Samandari T.
        • Bell B.P.
        Incidence of hepatitis A in the United States in the era of vaccination.
        JAMA. 2005; 294: 141-201
        • Staes C.J.
        • Schlenker T.L.
        • Risk I.
        • et al.
        Sources of infections among persons with acute hepatitis A and no identified risk factors during a sustained community-wide outbreak.
        Pediatrics. 2000; 106: e54
        • Smith P.F.
        • Grabau J.C.
        • Werzberger A.
        • et al.
        The role of young children in a community-wide outbreak of hepatitis A.
        Epidemiol Infect. 1997; 118: 243-252
        • American Academy of Pediatrics
        Hepatitis A.
        in: Pickering L.K. Baker C.J. Long S.S. McMillan J.A. Red Book: 2006 Report of the Committee on Infectious Diseases. 27th edition. American Academy of Pediatrics, Elk Grove Village (IL)2006: 326-335
        • Dong C.
        • Dai X.
        • Meng J.H.
        The first experimental study on a candidate combined vaccine against hepatitis A and hepatitis E.
        Vaccine. 2007; 25: 1662-1668
        • CDC
        Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices.
        MMWR Morb Mortal Wkly Rep. 2006; 55: 4-41
        • Neuzil K.M.
        • Mellen B.G.
        • Wright P.F.
        • et al.
        The effect of influenza on hospitalizations, outpatient visits and courses of antibiotics in children.
        N Engl J Med. 2000; 342: 225-231
        • Poehling K.A.
        • Edwards K.M.
        • Weinberg G.A.
        • et al.
        The under-recognized burden of influenza in young children.
        N Engl J Med. 2006; 355: 31-40
        • Bhat N.
        • Wright J.G.
        • Broder K.R.
        • et al.
        Influenza-associated deaths among children in the United States, 2003-2004.
        N Engl J Med. 2005; 353: 2559-2567
        • American Academy of Pediatrics
        Influenza.
        in: Pickering L.K. Baker C.J. Long S.S. McMillan J.A. Red Book: 2006 Report of the Committee on Infectious Diseases. 27th editor. American Academy of Pediatrics, Elk Grove Village (IL)2006: 401-411
        • Reichert T.A.
        • Sugaya N.
        • Fedson D.S.
        • et al.
        The Japanese experience with vaccinating school children against influenza.
        N Engl J Med. 2001; 344: 889-896
        • CDC
        Childhood influenza vaccination coverage—United States. 2004–2005, influenza season.
        MMWR Recomm Rep. 2006; 55: 1062-1065
        • King J.C.
        • Stoddard J.J.
        • Gaglani M.J.
        • et al.
        Effectiveness of school-based influenza vaccination.
        N Engl J Med. 2006; 355: 2523-2532
        • Schwartz B.
        • Hinman A.
        • Abramson J.
        • et al.
        Universal influenza vaccination in the United States: are we ready? Report of a meeting.
        J Infect Dis. 2006; 194: S147-S154
        • Ritzwoller D.P.
        • Bridges C.B.
        • Shetterley S.
        • et al.
        Effectiveness of the 2003–2004 influenza vaccine among children 6 months to 8 years of age with 1 vs 2 doses.
        Pediatrics. 2005; 116: 153-159
        • MedImmune
        Package insert, Flumist®.
        MedImmune, Gaithersburg, MD2006
        • Piedra P.A.
        • Gagliani M.J.
        • Riggs M.
        • et al.
        Live attenuated influenza vaccine, trivalent, is safe in healthy children 18 months to 4 years, 5 to 9 years and 10 to 18 years of age in a community-based, non-randomised, open-label trial.
        Pediatrics. 2005; 116: e397-e407
        • Meissner H.C.
        Influenza vaccines: a pediatric perspective.
        Curr Opin Pediatr. 2007; 19: 58-63
      22. MedImmune. Available at: http://www.medimmune.com/. Accessed January 7, 2007.

      23. Belshe R, Walker R, Hultquist M, et al. Immunogenicity of cold-adapted influenza vaccine, trivalent (CAIV-T) compared with trivalent inactivated influenza vaccine in children 6–35 months of age. Session 147. Presented at the 44th Annual Meeting of the Infectious Diseases Society of America. Toronto, October 12–15, 2006.

        • Gagliani M.
        • Riggs M.
        • Kamenicky C.
        • et al.
        A computerized reminder strategy is effective for annual influenza immunization of children with asthma or reactive airways disease.
        Pediatr Infect Dis J. 2001; 20: 1155-1160
        • Daley M.F.
        • barrow J.
        • Bearson K.
        • et al.
        Identification and recall of children with chronic medical conditions for influenza immunization.
        Pediatrics. 2004; 113: e26-e33
        • Ma K.K.
        • Schaffner W.
        • Colmenares C.
        • et al.
        Influenza vaccinations of young children increased with media coverage in 2003.
        Pediatrics. 2006; 117: 157-163
        • Mills E.
        • Gold R.
        • Thipphawong J.
        • et al.
        Safety and immunogenicity of a combined five-component pertussis-diphtheria-tetanus-inactivated poliomyelitis-Haemophilus B conjugate vaccine administered to infants at two, four and six months of age.
        Vaccine. 1998; 16: 576-585
      24. Noriega F, Tomovici A, Jemiolo D, et al. Safety and immunogenicity comparison of a fourth dose of DTaP-IPV/PRP-T (Pentacel®) to the separate administration of Daptacel® and ActHIB®. P3T06 Study group. Presented at the 43rd Annual Meeting of the Infectious Diseases Society of America [abstract 985]. San Francisco. October 6–9, 2005.

      25. Herz A, Black S, Shinefield H, et al. Safety of combined DTaP-IPV + PRP-T (Pentacel®) administered at 2, 4, 6 and 15 to 18 months of age. Pediatric Academic Societies Annual Meeting [abstract 1388]. Washington, DC, May 14–17, 2005.

      26. Noriega F, Tsang P, Jemiolo D, et al. Immunogenicity of a four dose series of DTaP-IPV//PRP-T (Pentacel®). The Pentacel Investigators Study Group Abstract 9. Presented at the 5th Pediatric Infectious Disease Conference. NAPA, CA, October 9–11, 2005.

        • Scheifele D.W.
        • Halperin S.A.
        • Smith B.
        • et al.
        Assessment of the compatibility of co-administered 7-valent pneumococcal conjugate, DTaP/IPV/PRP-T Hib and hepatitis B vaccines in infants 2-7 months of age.
        Vaccine. 2006; 24: 2057-2064
      27. Edwards KM, Tsang P, Wang L, et al. Safety and immunogenicity of DTap-IPV//PRP-T (Pentacel®) co-administered with pneumococcal conjugate vaccine (Prevnar®) at 2, 4 and 6 months of age [abstract 984]. For the M5A03 study group. Presented at the 43rd Annual Meeting of the Infectious Diseases Society of America. San Francisco, CA, October 6–6, 2005.

        • Halperin S.A.
        Prevention of pertussis across the age spectrum through the use of the combination vaccines PENTACEL® and ADACEL®.
        Expert Opin Biol Ther. 2006; 6: 807-821
        • Joloba M.L.
        • Windau A.
        • Bajaksouzian S.
        • et al.
        Pneumococcal conjugate vaccine serotypes of Streptococcus pneumoniae isolates and the antimicrobial susceptibility of such isolates in children with otitis media.
        Clin Infect Dis. 2001; 33: 1489-1494
        • CDC
        Preventing pneumococcal disease among infants and young children. Advisory Committee on Immunization Practices.
        MMWR Recomm Rep. 2000; 49: 1-35
        • American Academy of Pediatrics
        Policy statement: recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (Prevnar®) pneumococcal polysaccharide vaccine, and antibiotic prophylaxis.
        Pediatrics. 2000; 106: 362-366
        • CDC
        Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease-United States, 1998-2003.
        MMWR Recomm Rep. 2005; 54: 893-897
        • Black S.
        • Shinefield H.
        • Baxter R.
        • et al.
        Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente.
        Pediatr Infect Dis J. 2004; 23: 485-489
        • Toltzis P.
        • Jacobs M.R.
        The epidemiology of childhood pneumococcal disease in the United States in the era of conjugate vaccine use.
        Infect Dis Clin North Am. 2005; 19: 629-645
        • Lexau C.A.
        • Lynfield R.
        • Danila R.
        • et al.
        Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine.
        JAMA. 2005; 294: 2043-2051
        • Whitney C.J.
        • Farley M.M.
        • Hadler J.
        • et al.
        Increasing prevalence of multidrug resistant Streptococcus pneumoniae in the United States.
        N Engl J Med. 2000; 343: 1917-1924
        • McCormick Aw
        • Whitney C.G.
        • Farley M.M.
        • et al.
        Geographic diversity and temporal trends of antimicrobial resistance in Streptococcus pneumoniae in the United States.
        Nat Med. 2003; 9: 424-430
        • Kyaw M.H.
        • Lynfield R.
        • Schaffner S.
        • et al.
        Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae.
        N Engl J Med. 2006; 354: 1455-1463
        • Klugman K.P.
        • Madhi S.A.
        • Huebner R.E.
        • et al.
        A trial of a 9-valent pneumococcal conjugate vaccine in children with and without HIV infection.
        N Engl J Med. 2003; 349 (1341)
        • French N.
        • Nakiyingi J.
        • Carpenter L.M.
        • et al.
        23-valent pneumococcal polysaccharide vaccine in HIV-I infected Ugandan adults: double blind, randomized and placebo controlled trial.
        Lancet. 2000; 355: 2106-2111
      28. Farrell D. Emergence and spread of multiresistant Streptococcus pneumoniae serotype 19A clone in the USA: focus on the pediatric population. Presented at the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; San Francisco, September 27–30, 2006.

        • Farrell D.J.
        • Klugman K.P.
        • Pichichero M.
        Increased antimicrobial resistance among nonvaccine serotypes of Streptococcus pneumoniae in the pediatric population after the introduction of 7-valent pneumococcal vaccine in the United States.
        Pediatr Infect Dis J. 2007; 26: 123-128